ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > 4-1BB > 41B-H5258

Human 4-1BB / TNFRSF9 Protein, Fc Tag (MALS verified)

  • Synonym
    TNFRSF9,4-1BB,CD137,CDw137,ILA
  • Source
    Human 4-1BB, Fc Tag(41B-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # NP_001552.2).
    Predicted N-terminus: Leu 24
  • Molecular Characterization
    4-1BB Structure

    This protein carries a human IgG1 Fc tag at the C-terminus

    The protein has a calculated MW of 43.4 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
4-1BB SDS-PAGE

Human 4-1BB, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS
4-1BB MALS images

The purity of Human 4-1BB, Fc Tag (Cat. No. 41B-H5258) is more than 90% and the molecular weight of this protein is around 90-110 kDa verified by SEC-MALS.

Bioactivity-ELISA
 4-1BB ELISA

Immobilized Human 4-1BB, Fc Tag (Cat. No. 41B-H5258) at 0.1 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB Ligand, Fc,Avitag (Cat. No. 41L-H82F9) with a linear range of 0.4-6 ng/mL (QC tested).

 4-1BB ELISA

Immobilized Human 4-1BB, Fc Tag (Cat. No. 41B-H5258) at 1 μg/mL (100 μL/well) can bind Anti-Human 4-1BB MAb, Human IgG4 with a linear range of 0.2-3 ng/mL (Routinely tested).

 4-1BB ELISA

Immobilized Human 4-1BB, Fc Tag (Cat. No. 41B-H5258) at 1 μg/mL (100 μL/well) can bind Utomilumab with a linear range of 2-31 ng/mL (Routinely tested).

Bioactivity-BLI
 4-1BB BLI

Loaded Human 4-1BB, Fc Tag (Cat. No. 41B-H5258) on Protein A Biosensor, can bind Human 4-1BB Ligand, His Tag (Cat. No. 41L-H5249) with an affinity constant of 1.3 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Bioactivity-FACS
 4-1BB FACS

Flow Cytometry assay shows that Human 4-1BB, Fc Tag (Cat. No. 41B-H5258) can bind to 293T cells overexpressing Human 4-1BBL. The concentration of 4-1BB used is 0.1 μg/mL (Routinely tested).

  • Background
    4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 81,200

価格(JPY) : 602,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:65 Details
  • Latest Research Phase:Phase 3 Clinical

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone